Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy
| Autor: | Loukia Psaridi-Linardaki, Nikos Trakas, Socrates J. Tzartos, Avgi Mamalaki |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
animal structures
Time Factors medicine.medical_treatment Immunology Pharmacology Receptors Nicotinic Pichia Epitopes Plasma Antibody Specificity Myasthenia Gravis medicine Extracellular Equipment Reuse Immunology and Allergy Humans Immunoadsorption Muscle Skeletal Immunosorbent Techniques Acetylcholine receptor Autoantibodies biology Chemistry Hydrolysis Autoantibody medicine.disease Myasthenia gravis Peptide Fragments Protein Structure Tertiary Nicotinic acetylcholine receptor Protein Subunits Neurology Immunoglobulin G biology.protein Plasmapheresis Neurology (clinical) Binding Sites Antibody Antibody Extracellular Space Peptide Hydrolases |
| Zdroj: | Journal of neuroimmunology. 159(1-2) |
| ISSN: | 0165-5728 |
| Popis: | Antibodies against the acetylcholine receptor (AChR) are the main pathogenic factor in myasthenia gravis (MG). Clinical improvement correlates well with a reduction in levels of circulating anti-AChR antibodies, and plasmapheresis is an efficient short-term MG treatment. The Sepharose-immobilized N-terminal extracellular domain of human muscle AChR α-subunit was used to immunoadsorb anti-AChR autoantibodies from 50 MG patients sera. The immunoadsorbents removed 60–94% of the anti-AChR antibodies in 10 sera and a mean of 35% from all samples combined. Immunoadsorption was fast, efficient, and the columns could be used repeatedly without any release or proteolysis of the polypeptide, suggesting the feasibility of antigen-specific MG immunoadsorption therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect